Coyne Terrance P. 4
4 · Royalty Pharma plc · Filed Feb 25, 2026
Insider Transaction Report
Form 4
Coyne Terrance P.
EVP & CFO
Transactions
- Sale
Class A Ordinary Shares
[F1][F2]2026-02-23$45.32/sh−32,916$1,491,638→ 131,664 total(indirect: By LLC) - Sale
Class A Ordinary Shares
[F1][F2]2026-02-23$45.32/sh−1,875$84,968→ 47,636 total(indirect: By LLC)
Holdings
- 24,170(indirect: By Spouse)
Class A Ordinary Shares
- 23,270(indirect: By IRA)
Class A Ordinary Shares
- 1,500
Class A Ordinary Shares
- 1,450(indirect: By Spouse)
Class A Ordinary Shares
Footnotes (2)
- [F1]All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.97 to $45.60 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Signature
/s/ Sean Weisberg, as Attorney-in-Fact for Terrance P. Coyne|2026-02-25